special report by epic research 30-01-2013

Upload: matthew-fuller

Post on 04-Apr-2018

216 views

Category:

Documents


0 download

TRANSCRIPT

  • 7/29/2019 Special Report by Epic Research 30-01-2013

    1/5

    30TH January 2013

    DAILY CHARTIST

    VIEW

  • 7/29/2019 Special Report by Epic Research 30-01-2013

    2/5

    HIGHLIGHTS

    A

    Highlights

    Nifty traded volatile and ended negative on Tuesday

    Nifty Future ended 27.80 points down at 6049.40

    IVRCL future sell call hits both tgs and made low 30.95

    and Sun Tv future sell call remained unexecuted.

    Investors are advised to book full profit in IVRCL future

    and take position in fresh calls provided below.

    Buy ITC future above 306 for targets 309/313 with sl

    301.45Sell Biocon future below 278 for targets 275/271 with sl

    282.45.

    Past Performance:

    IVRCL Infra sell call hits final tg 34, made low 30.95.

    Sun Tv future sell call remained unexecuted.

    Jet Airways buy call hits final tg 630.

    HUL future sell call made low 466.50.

    Andhra Bank future sell call made low 107.70

    ITC future buy call made high 300.45.

    Bharti Airtel future buy call made high 369.30

  • 7/29/2019 Special Report by Epic Research 30-01-2013

    3/5

    Buy ITC future above 306

    ITC future is making a Channel Line pattern on 15

    minutes charts.

    Currently trading at 304.80

    Investors are advised to buy above 306, break out is yet

    to come.

    Targets are 309/313 and SL is recommended at 301.45.

    This is an intraday call as the pattern is forming on 51

    minutes chart.

    ITC FUTURE CHANNEL LINE

    BUY ABOVE306 FOR TARGETS 309/313 SL 301.45

  • 7/29/2019 Special Report by Epic Research 30-01-2013

    4/5

    Sell Biocon future below 278

    Biocon future is making a Rising wedge pattern on 15

    minutes chart.

    Currently trading at 278.95

    Investors are advised to sell below 278 for targets

    275/271, Breakout is yet to come.

    Targets are 275/271 and SL recommended is 282.45

    BIOCON FUTURE RISING WEDGE

    SELL BELOW 278 FOR TARGETS 275/271 SL 282.45

  • 7/29/2019 Special Report by Epic Research 30-01-2013

    5/5

    Disclaimer

    The information and view in this report, our website & all the service we provideare believed to be reliable, but we do not accept any responsibility (or liability) forerrors of fact or opinion. Users have the right to choose the product/s that suitsthem the most.

    Sincere efforts have been made to present the right investment perspective. The

    information contained herein is based on analysis and up on sources that weconsider reliable.

    This material is for personal information and based upon it & takes noresponsibility

    The information given herein should be treated as only factor, while makinginvestment decision. The report does not provide individually tailor-madeinvestment advice. Epic research recommends that investors independentlyevaluate particular investments and strategies, and encourages investors to seekthe advice of a financial adviser. Epic research shall not be responsible for anytransaction conducted based on the information given in this report, which is inviolation of rules and regulations of NSE and BSE.

    The share price projections shown are not necessarily indicative of future priceperformance. The information herein, together with all estimates and forecasts, canchange without notice. Analyst or any person related to epic research might beholding positions in the stocks recommended. It is understood that anyone who isbrowsing through the site has done so at his free will and does not read any viewsexpressed as a recommendation for which either the site or its owners oranyone can be held responsible for . Any surfing and reading of the information isthe acceptance of this disclaimer.

    All Rights Reserved. Investment in equity & bullion market has its own risks.

    We, however, do not vouch for the accuracy or the completeness thereof. we are notresponsible for any loss incurred whatsoever for any financial profits or losswhich may arise from the recommendations above epic research does not purportto be an invitation or an offer to buy or sell any financial instrument. Our Clients(Paid Or Unpaid), Any third party or anyone else have no rights to forward orshare our calls or SMS or Report or Any other information provided by us to/withanyone which is related directly or indirectly with them. If found so, then Serious

    Legal Actions can be taken.